Author(s):
Shivraj Popat Jadhav, Sushant Mothabhau Ahire, Nilesh Ramkrushna Chitte, Prerana Sharad Pawar, Indrakumar Sonawane, Vijay Shewale
Email(s):
shiva.007ind@gmail.com
DOI:
10.52711/2231-5659.2026.00035 
Address:
Shivraj Popat Jadhav1*, Sushant Mothabhau Ahire2, Nilesh Ramkrushna Chitte3, Prerana Sharad Pawar1, Indrakumar Sonawane1, Vijay Shewale4
1Department of Pharmaceutics, Divine College of Pharmacy, Satana, Nashik, Maharashtra, India, 423301.
2Department of Pharmaceutical Chemistry, Divine College of Pharmacy, Satana, Nashik, Maharashtra, India, 423301.
3Department of Pharmaceutics, R G Sapkal College of Pharmacy, Nashik, Maharashtra, India, 422212.
4Department of Pharmacognosy, Divine College of Pharmacy, Satana, Nashik, Maharashtra, India, 423301.
*Corresponding Author
Published In:
Volume - 16,
Issue - 3,
Year - 2026
ABSTRACT:
The blood–brain barrier (BBB) is an extremely choosy physiological border that preserves central nervous system (CNS) homeostasis and restricts the entry of certain drugs, causing a major obstacle in the treatment of neurological disorders. Conventional approaches to cross the BBB—such as chemical modification of drugs, osmotic disruption, and invasive administration—have provided limited success due to issues of invasiveness, safety, and poor specificity. Advances in nanotechnology have introduced lipid-based carriers, polymeric nanoparticles, dendrimers, micelles, and nanosponges, offering improved biocompatibility, controlled release, and active targeting capabilities. Biological and receptor-mediated strategies, including receptor-mediated transport, carrier-mediated systems, cell-penetrating peptides, and monoclonal antibody “Trojan horse” approaches, exploit endogenous transport pathways for more selective brain delivery. Emerging technologies such as exosome-mediated transport, gene therapy vectors, CRISPR/Cas-based genome editing, nanobody conjugates, and hybrid nanoparticles are expanding the therapeutic landscape, with the potential to transform treatment paradigms for neurodegenerative diseases, brain tumors, and genetic disorders. Despite these advancements, challenges persist, including limited transport efficiency, receptor competition, immune responses, and regulatory hurdles. Future directions emphasize personalized medicine, artificial BBB models and organ-on-chip systems for predictive screening, and careful consideration of ethical and translational challenges. Collectively, these multidisciplinary innovations are expected to transform the BBB from a barrier into a gateway, enabling safe and effective delivery of next-generation CNS therapies.
Cite this article:
Shivraj Popat Jadhav, Sushant Mothabhau Ahire, Nilesh Ramkrushna Chitte, Prerana Sharad Pawar, Indrakumar Sonawane, Vijay Shewale. Crossing the Blood–Brain Barrier: Challenges, Strategies and Emerging Technologies. Asian Journal of Research in Pharmaceutical Sciences. 2026; 16(3):234-2. doi: 10.52711/2231-5659.2026.00035
Cite(Electronic):
Shivraj Popat Jadhav, Sushant Mothabhau Ahire, Nilesh Ramkrushna Chitte, Prerana Sharad Pawar, Indrakumar Sonawane, Vijay Shewale. Crossing the Blood–Brain Barrier: Challenges, Strategies and Emerging Technologies. Asian Journal of Research in Pharmaceutical Sciences. 2026; 16(3):234-2. doi: 10.52711/2231-5659.2026.00035 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2026-16-3-4
12. REFERENCES:
1. Daneman R, Prat A. The Blood–Brain Barrier. Cold Spring Harb Perspect Biol. 2015 Jan;7(1): a020412. doi:10.1101/cshperspect. a020412.
2. Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood–brain barrier: Structure, regulation and drug delivery. Sig Transduct Target Ther. 2023 May;8(1):217. doi:10.1038/s41392-023-01481-w.
3. Feigin VL, Vos T, Nichols E, Owolabi MO, Carroll WM, Dichgans M, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020 Mar;19(3):255–65. doi:10.1016/S1474-4422(19)30411-9.
4. Pardridge WM. The blood–brain barrier: Bottleneck in brain drug development. Neurotherapeutics. 2005 Jan; 2(1): 3–14. doi:10.1602/neurorx.2.1.3.
5. Sharma A, Dhiman K, Sharma A, Goyal K, Pandit V, Ashawat MS, Jindal S. Application of nanocarrier in drug development with special emphasis on liposomes: a review. Asian J Pharm Technol. 2022; 12(4): 320–8.
6. McConnell HL, Mishra A. Cells of the Blood–Brain Barrier: An Overview of the Neurovascular Unit in Health and Disease. In: Stone N, editor. The Blood–Brain Barrier. New York (NY): Springer US; 2022;3–24. (Methods in Molecular Biology; vol. 2492). doi:10.1007/978-1-0716-2289-61
7. Luissint AC, Artus C, Glacial F, Ganeshamoorthy K, Couraud PO. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS. 2012 Dec;9(1):23. doi:10.1186/2045-8118-9-23.
8. Watkins S, Robel S, Kimbrough IF, Robert SM, Ellis-Davies G, Sontheimer H. Disruption of astrocyte–vascular coupling and the blood–brain barrier by invading glioma cells. Nat Commun. 2014 Jun;5(1):4196. doi:10.1038/ncomms5196.
9. Stratman AN, Davis GE. Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization. Microsc Microanal. 2012 Feb; 18(1): 68–80. doi:10.1017/S1431927611012402.
10. Barar J, Rafi MA, Pourseif MM, Omidi Y. Blood–brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts. 2016 Dec; 6(4): 225–48. doi:10.15171/bi.2016.30.
11. Ronaldson PT, Davis TP. Transport mechanisms at the blood–brain barrier and in cellular compartments of the neurovascular unit: focus on CNS delivery of small molecule drugs. Pharmaceutics. 2022 Jul; 14(7): 1501. doi:10.3390/pharmaceutics14071501.
12. Alajangi HK, Kaur M, Sharma A, Rana S, Thakur S, Chatterjee M, et al. Blood–brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders. Mol Brain. 2022 Dec; 15(1): 49. doi:10.1186/s13041-022-00937-4.
13. Hajal C, Campisi M, Mattu C, Chiono V, Kamm RD. In vitro models of molecular and nano-particle transport across the blood–brain barrier. Biomicrofluidics. 2018 Jul; 12(4): 042213. doi:10.1063/1.5027118.
14. Mikitsh JL, Chacko AM. Pathways for small molecule delivery to the central nervous system across the blood–brain barrier. Perspect Medicin Chem. 2014 Jan; 6: PMC.S13384. doi:10.4137/PMC.S13384.
15. Sirisha S, Praveena R. A complete review – nanoparticles targeting to brain. Asian J Res Pharm Sci. 2020; 10(3): 199. doi:10.5958/2231-5659.2020.00038.7.
16. Upton DH, Ung C, George SM, Tsoli M, Kavallaris M, Ziegler DS. Challenges and opportunities to penetrate the blood–brain barrier for brain cancer therapy. Theranostics. 2022; 12(10): 4734–52. doi:10.7150/thno.69682.
17. Sirisha S. A review on delivery of anti-cancer drugs by smart nanocarriers: data obtained from past one decade. Res J Pharm Dosage Forms Technol. 2020; 12(3): 185–90.
18. Leclerc M, Dudonné S, Calon F. Can natural products exert neuroprotection without crossing the blood–brain barrier? Int J Mol Sci. 2021 Mar; 22(7): 3356. doi:10.3390/ijms22073356.
19. Hersh DS, Wadajkar AS, Roberts NB, Perez JG, Connolly NP, Frenkel V, et al. Evolving drug delivery strategies to overcome the blood–brain barrier. Curr Pharm Des. 2016 Mar; 22(9): 1177–93. doi:10.2174/1381612822666151221150733.
20. Lu CT, Zhao YZ, Wong HL, Cai J, Peng L, Tian XQ. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine. 2014 May; 2241. doi:10.2147/IJN.S61288.
21. McLoughlin CD, Nevins S, Stein JB, Khakbiz M, Lee K. Overcoming the blood–brain barrier: multifunctional nanomaterial-based strategies for targeted drug delivery in neurological disorders. Small Sci. 2024 Dec; 4(12): 2400232. doi:10.1002/smsc.202400232.
22. Gernert M, Feja M. Bypassing the blood–brain barrier: direct intracranial drug delivery in epilepsies. Pharmaceutics. 2020 Nov; 12(12): 1134. doi:10.3390/pharmaceutics12121134.
23. Teixeira MI, Lopes CM, Amaral MH, Costa PC. Surface-modified lipid nanocarriers for crossing the blood–brain barrier (BBB): a current overview of active targeting in brain diseases. Colloids Surf B Biointerfaces. 2023 Jan; 221: 112999. doi: 10.1016/j.colsurfb.2022.112999.
24. Satapathy T, Panda PK. Solid lipid nanoparticles: a novel carrier in drug delivery system. Res J Pharm Dosage Forms Technol. 2013;5(2):56–61.
25. Zhang W, Mehta A, Tong Z, Esser L, Voelcker NH. Development of polymeric nanoparticles for blood–brain barrier transfer—strategies and challenges. Adv Sci. 2021 May; 8(10): 2003937. doi:10.1002/advs.202003937.
26. Wu Y, Moonshi SS, Ta HT. Advancements in using polymeric nanoparticles for blood–brain barrier penetration in neurological disorders. ACS Appl Bio Mater. 2025 Jun; 8(6): 4416–31. doi:10.1021/acsabm.4c01956.
27. Ravind M, Kumar PS, Begum SKA. An overview of dendrimers as novel carriers in drug delivery. Res J Pharm Technol. 2023; 16(4): 2051–6.
28. Wang J, Wang Z, Zhang G, Rodrigues J, Tomás H, Shi X, et al. Blood–brain barrier-crossing dendrimers for glioma theranostics. Biomater Sci. 2024;12(6):1346–56. doi:10.1039/D4BM00043A.
29. Abdelsalam M, Ahmed M, Osaid Z, Hamoudi R, Harati R. Insights into exosome transport through the blood–brain barrier and the potential therapeutical applications in brain diseases. Pharmaceuticals. 2023 Apr; 16(4): 571. doi:10.3390/ph16040571.
30. Alrubaye YSJ, Mohammed MB, Abdulamir HA. Exosome and breast cancer. Res J Pharm Technol. 2022; 15(3): 1393–7.
31. Jones AR, Shusta EV. Blood–brain barrier transport of therapeutics via receptor-mediation. Pharm Res. 2007 Aug;24(9):1759–71. doi:10.1007/s11095-007-9379-0.
32. Ding L, Kshirsagar P, Agrawal P, Murry DJ. Crossing the blood–brain barrier: innovations in receptor- and transporter-mediated transcytosis strategies. Pharmaceutics. 2025 May; 17(6): 706. doi:10.3390/pharmaceutics17060706.
33. Xie J, Bi Y, Zhang H, Dong S, Teng L, Lee RJ, et al. Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application. Front Pharmacol. 2020 May; 11:697. doi:10.3389/fphar.2020.00697.
34. Pardridge WM. Molecular Trojan horses for blood–brain barrier drug delivery. Curr Opin Pharmacol. 2006 Oct; 6(5): 494–500. doi: 10.1016/j.coph.2006.06.001.
35. Patel KK, Patel BS, Prajapati A, Narkhede SB, Luhar S. The exosome revolution: bridging early detection and personalized treatment. Res J Pharm Dosage Forms Technol. 2025; 17(1): 26–30.
36. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019 May; 18(5): 358–78. doi:10.1038/s41573-019-0012-9.
37. PM. Patil, PD Chaudhari, Megha Sahu, NJ Duragkar. Review Article on Gene Therapy. Research J. Pharmacology and Pharmacodynamics. 2012; 4(2): 77-83.
38. Nouri Nojadeh J, Bildiren Eryılmaz NS, Ergüder Bİ. CRISPR/Cas9 genome editing for neurodegenerative diseases. EXCLI J. 2023; 22: Doc567. doi:10.17179/EXCLI2023-6155
39. Swapnaa B, Santhosh Kumar V. Personalized Medicine - A Novel approach in Cancer Therapy. Research J. Pharm. and Tech. 2017; 10(1): 341-345.\
40. P. V. Kamala Kumari, Y. Srinivasa Rao. Personalized Medicine- A Review. Research J. Pharm. and Tech 2019; 12(8):3989-3992.
41. Chaulagain B, Gothwal A, Lamptey RNL, Trivedi R, Mahanta AK, Layek B, et al. Experimental models of in vitro blood–brain barrier for CNS drug delivery: an evolutionary perspective. Int J Mol Sci. 2023 Jan; 24(3): 2710. doi:10.3390/ijms24032710.